GPER1 as a Chemopreventive Target in Prostate Cancer Progression

Study Background and Research Question

Prostate cancer (PCa) remains one of the leading malignancies affecting men globally, with incidence rates projected to rise significantly by 2040. The disease typically progresses from high-grade prostatic intraepithelial neoplasia (HGPIN) through well-differentiated carcinoma stages, presenting a latency window during which preventive interventions could be especially effective. While traditional chemopreventive strategies—such as 5α-reductase inhibitors and micronutrient supplementation—have yielded mixed results, the search for molecular targets that could halt or slow progression remains a priority. G-protein coupled estrogen receptor 1 (GPER1) has recently emerged as a candidate of interest, owing to prior indications of its tumor-suppressive effects in other cancer systems. The central research question posed by Desouza et al. (2025) is whether GPER1 acts as a protective factor during prostate carcinogenesis and if its activation could be harnessed for chemoprevention.

Key Innovation from the Reference Study

The principal innovation of this work lies in its systematic evaluation of GPER1 as a chemopreventive target in prostate cancer—a question not previously addressed in this level of detail. Unlike prior studies, which focused primarily on the anti-proliferative effects of GPER1 activation in established cancer cells, the current study interrogates the receptor’s role at early, pre-malignant stages using both human tissue samples and the transgenic adenocarcinoma of mouse prostate (TRAMP) model. A further methodological advance is the use of selective GPER1 agonists and antagonists in both in vivo and in vitro systems, allowing for precise attribution of observed effects to this receptor.

Methods and Experimental Design Insights

The authors employ a multi-pronged approach:

• Bioinformatic Analysis: Public gene expression datasets were mined to compare GPER1 levels between non-cancerous and various stages of prostate cancer tissue.
• Histological Validation: Human primary prostate cancer specimens and TRAMP mouse prostates were assessed for GPER1 expression by immunohistochemistry and quantitative PCR.
• Functional Manipulation in vivo: At the HGPIN stage in TRAMP mice, the selective GPER1 agonist G1 was administered, alone or in combination with the antagonist G15, to test the impact on lesion progression.
• In vitro Cell Line Assays: The LNCaP, PC3, and RWPE-1 prostate epithelial cell lines were subjected to GPER1 activation or silencing, followed by measurements of proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) markers.

This design enables the authors to dissect both the correlative and causative roles of GPER1 in prostate carcinogenesis, as well as to define downstream molecular mechanisms.

Core Findings and Why They Matter

The study provides several lines of evidence for a protective role of GPER1:

• Expression Dynamics: GPER1 expression is elevated in HGPIN lesions compared to non-tumorous tissue, but declines significantly in advanced prostate cancer, both in human samples and TRAMP mice. This pattern suggests a stage-specific protective function.
• Chemopreventive Effect in vivo: Activation of GPER1 using G1 at the HGPIN stage in TRAMP mice suppressed the progression to carcinoma. This effect was negated by co-administration of the antagonist G15, confirming specificity of the pathway.
• Inhibition of Malignant Phenotypes in vitro: G1-mediated GPER1 activation reduced proliferation in LNCaP, PC3, and RWPE-1 cell lines. Conversely, GPER1 silencing promoted migration, invasion, and EMT, mechanistically linked to dysregulation of the miR200a–ZEB2–E-cadherin axis and upregulation of metastasis-associated genes.

Collectively, these findings suggest that GPER1 activity restrains the malignant transformation of prostate epithelial cells and modulates EMT, a critical process in cancer metastasis. This positions GPER1 as a promising target for preventive intervention, particularly during the prolonged pre-cancerous phase of PCa development.

Comparison with Existing Internal Articles

While the present study focuses on GPER1 and prostate cancer, there are thematic connections to research in renal pathology, particularly regarding the molecular mechanisms underlying epithelial-mesenchymal transition and tissue remodeling. For example, articles such as "Puromycin Aminonucleoside: Mechanistic Precision and Strategy" discuss how the aminonucleoside moiety of puromycin is used to induce podocyte injury and glomerular lesions in nephrology research. These models rely on detailed understanding of epithelial cell plasticity—a concept that also underlies EMT in cancer biology. The methodological rigor in modeling cellular injury with compounds such as puromycin aminonucleoside parallels the precision with which GPER1 signaling was manipulated in the prostate cancer context. Furthermore, insights from "Puromycin aminonucleoside advances proteinuria and podocyte injury research" highlight the importance of transporter-specific uptake and the downstream effects on cell morphology, reminiscent of the EMT-driven changes observed in both podocyte damage and cancer progression. Thus, molecular tools and injury models developed in one organ system can inform mechanistic and translational studies in another, underscoring the value of cross-disciplinary approaches.

Limitations and Transferability

While the evidence for GPER1’s protective and chemopreventive functions is compelling, several limitations should be noted. First, much of the direct functional data stems from the TRAMP mouse model, which, despite its utility, may not fully recapitulate human disease heterogeneity. Second, pharmacological targeting of GPER1 in the clinical setting remains speculative, as agonists with favorable safety profiles and pharmacokinetics are not yet clinically available. Third, the observed effects on EMT and metastatic gene expression were demonstrated in vitro; their translation to in vivo contexts, especially in human disease, requires further validation. Finally, the study does not address potential off-target or systemic effects of modulating GPER1 signaling, which could influence tissue homeostasis elsewhere.

Protocol Parameters

• GPER1 agonist administration in vivo: Begin at HGPIN stage in TRAMP mice; dosing and duration should be optimized based on pilot studies.
• GPER1 antagonist co-treatment: Use G15 to confirm specificity of observed effects; co-administer with G1 as a negative control.
• In vitro EMT assessment: Employ siRNA-mediated GPER1 silencing in prostate epithelial cell lines; measure migration, invasion, and EMT markers (e.g., E-cadherin, ZEB2).
• Bioinformatic analysis: Compare GPER1 expression across stages using publicly available gene expression datasets; validate findings with human clinical samples where possible.

Research Support Resources

For researchers interested in modeling injury responses, epithelial plasticity, or chemopreventive interventions, robust experimental systems are essential. In nephrology and renal pathology, the Puromycin aminonucleoside (SKU A3740) is widely used for the reproducible induction of podocyte injury and glomerular lesions, facilitating studies on proteinuria, FSGS, and mechanisms of epithelial-mesenchymal transition in the kidney. According to the product information, this aminonucleoside moiety of puromycin is suitable for both in vivo and in vitro models, supporting workflows that require precise control over injury induction and cellular phenotype transitions. Its utility in nephrotoxic and podocyte injury models provides methodological parallels for cancer researchers interested in EMT, tissue remodeling, and chemopreventive strategy validation.